Literature DB >> 15899888

The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.

Daniel Duran-Sandoval1, Bertrand Cariou, Fredéric Percevault, Nathalie Hennuyer, Aldo Grefhorst, Theo H van Dijk, Frank J Gonzalez, Jean-Charles Fruchart, Folkert Kuipers, Bart Staels.   

Abstract

The liver plays a central role in the control of blood glucose homeostasis by maintaining a balance between glucose production and utilization. The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor. Hepatic FXR expression is regulated by glucose and insulin. Here we identify a role for FXR in the control of hepatic carbohydrate metabolism. When submitted to a controlled fasting-refeeding schedule, FXR(-/-) mice displayed an accelerated response to high carbohydrate refeeding with an accelerated induction of glycolytic and lipogenic genes and a more pronounced repression of gluconeogenic genes. Plasma insulin and glucose levels were lower in FXR(-/-) mice upon refeeding the high-carbohydrate diet. These alterations were paralleled by decreased hepatic glycogen content. Hepatic insulin sensitivity was unchanged in FXR(-/-) mice. Treatment of isolated primary hepatocytes with a synthetic FXR agonist attenuated glucose-induced mRNA expression as well as promoter activity of L-type pyruvate kinase, acetyl-CoA carboxylase 1, and Spot14. Moreover, activated FXR interfered negatively with the carbohydrate response elements regions. These results identify a novel role for FXR as a modulator of hepatic carbohydrate metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899888     DOI: 10.1074/jbc.M501931200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  The effects of time-restricted feeding on lipid metabolism and adiposity.

Authors:  Amandine Chaix; Amir Zarrinpar
Journal:  Adipocyte       Date:  2015-04-20       Impact factor: 4.534

2.  Bile acid receptor agonist GW4064 regulates PPARγ coactivator-1α expression through estrogen receptor-related receptor α.

Authors:  Shailendra Kumar Dhar Dwivedi; Nidhi Singh; Rashmi Kumari; Jay Sharan Mishra; Sarita Tripathi; Priyam Banerjee; Priyanka Shah; Vandana Kukshal; Abdul Malik Tyagi; Anil Nilkanth Gaikwad; Rajnish Kumar Chaturvedi; Durga Prasad Mishra; Arun Kumar Trivedi; Somali Sanyal; Naibedya Chattopadhyay; Ravishankar Ramachandran; Mohammad Imran Siddiqi; Arun Bandyopadhyay; Ashish Arora; Thomas Lundåsen; Sayee Priyadarshini Anakk; David D Moore; Sabyasachi Sanyal
Journal:  Mol Endocrinol       Date:  2011-04-14

Review 3.  Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease.

Authors:  Jeff L Staudinger; Kristin Lichti
Journal:  Mol Pharm       Date:  2007-12-27       Impact factor: 4.939

Review 4.  Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs.

Authors:  Tiara R Ahmad; Rebecca A Haeusler
Journal:  Nat Rev Endocrinol       Date:  2019-10-15       Impact factor: 43.330

5.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

Authors:  Yanqiao Zhang; Florence Ying Lee; Gabriel Barrera; Hans Lee; Charisse Vales; Frank J Gonzalez; Timothy M Willson; Peter A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

6.  Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes.

Authors:  Sandrine Caron; Carolina Huaman Samanez; Hélène Dehondt; Maheul Ploton; Olivier Briand; Fleur Lien; Emilie Dorchies; Julie Dumont; Catherine Postic; Bertrand Cariou; Philippe Lefebvre; Bart Staels
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

7.  FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.

Authors:  Sabrina Cipriani; Andrea Mencarelli; Giuseppe Palladino; Stefano Fiorucci
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

Review 8.  Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

Authors:  Vivian A Fonseca; Yehuda Handelsman; Bart Staels
Journal:  Diabetes Obes Metab       Date:  2010-05       Impact factor: 6.577

9.  Bile acid sequestrants for lipid and glucose control.

Authors:  Bart Staels; Yehuda Handelsman; Vivian Fonseca
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

Review 10.  Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration.

Authors:  Bart Staels; Vivian A Fonseca
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.